Literature DB >> 10735610

Serum laminin and type IV collagen are accurate markers of histologically severe alcoholic hepatitis in patients with cirrhosis.

L Castera1, D J Hartmann, F Chapel, C Guettier, F Mall, T Lons, J P Richardet, S Grimbert, O Morassi, M Beaugrand, J C Trinchet.   

Abstract

BACKGROUND/AIMS: Severe alcoholic hepatitis occurs mainly in patients with cirrhosis, and has a high death rate. Corticosteroid therapy has been particularly advocated as reducing mortality in patients with severe histologic lesions. However, identification of these patients is difficult, requiring transvenous liver biopsy. Extracellular matrix serum markers have been proposed as non-invasive diagnostic tools in alcoholic liver disease. The aim of this study was to determine the accuracy of 5 extracellular matrix serum markers, i.e. laminin (Lam), N-terminal peptide of type III procollagen (PIIINP), type I (CI), type III (CIII) and type IV (CIV) collagens in identifying patients with severe histologic alcoholic hepatitis from among those with cirrhosis and suspected alcoholic hepatitis.
METHODS: We studied 80 consecutive patients with alcoholic cirrhosis and clinical suspicion of alcoholic hepatitis referred for transvenous liver biopsy. Clinical severity of alcoholic hepatitis was assessed according to Maddrey's score. Histological severity was scored using the sum of the 3 following items: polynuclear infiltration (0-3); hepatocytes alterations (0-3); Mallory bodies (0-2). According to this score, patients were divided into 3 groups: mild (1-3), moderate (4-6), and severe (7-8) alcoholic hepatitis. Serum levels of the 5 extracellular matrix serum markers were measured at the time of biopsy using radioimmunoassays. Diagnostic value for histologically severe alcoholic hepatitis of the 5 extracellular matrix serum markers was assessed using receiver operating characteristic curves.
RESULTS: Histological alcoholic hepatitis was present in 67 patients (mean alcoholic hepatitis score: 3.4+/-2.3). Maddrey's score was 66% sensitive and 69% specific for the diagnosis of severe histologic alcoholic hepatitis. The serum Lam and CIV concentrations were the most accurate in identifying correctly patients with severe histologic alcoholic hepatitis. At a cut-off of 4.1 UI/ml, Lam was 90% sensitive and 77% specific, whereas at a cut-off of 150 ng/ml, CIV was 89% sensitive and 77% specific. Combination of markers did not result in improved diagnostic value.
CONCLUSION: In patients with cirrhosis, determination of serum Lam or CIV could represent a simple and accurate non-invasive method for identification of patients with histologically severe alcoholic hepatitis eligible for corticosteroid treatment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10735610     DOI: 10.1016/s0168-8278(00)80391-8

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  18 in total

Review 1.  Noninvasive diagnosis of liver fibrosis in patients with chronic hepatitis C.

Authors:  Laurent Castera; Jean-Michel Pawlotsky
Journal:  MedGenMed       Date:  2005-11-09

2.  Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score.

Authors:  E H Forrest; C D J Evans; S Stewart; M Phillips; Y H Oo; N C McAvoy; N C Fisher; S Singhal; A Brind; G Haydon; J O'Grady; C P Day; P C Hayes; L S Murray; A J Morris
Journal:  Gut       Date:  2005-08       Impact factor: 23.059

3.  Predicting mortality by the Glasgow alcoholic hepatitis score: the long awaited progress?

Authors:  H Tilg; A Kaser
Journal:  Gut       Date:  2005-08       Impact factor: 23.059

4.  Paediatric cholestatic liver disease: Diagnosis, assessment of disease progression and mechanisms of fibrogenesis.

Authors:  Tamara N Pereira; Meagan J Walsh; Peter J Lewindon; Grant A Ramm
Journal:  World J Gastrointest Pathophysiol       Date:  2010-06-15

5.  Clinical observation of salvianolic acid B in treatment of liver fibrosis in chronic hepatitis B.

Authors:  Ping Liu; Yi-Yang Hu; Cheng Liu; Da-Yuan Zhu; Hui-Ming Xue; Zhi-Qiang Xu; Lie-Ming Xu; Cheng-Hai Liu; Hong-Tu Gu; Zhi-Qing Zhang
Journal:  World J Gastroenterol       Date:  2002-08       Impact factor: 5.742

6.  Relationship between clinical and pathologic findings in patients with chronic liver diseases.

Authors:  Lun-Gen Lu; Min-De Zeng; Yi-Min Mao; Ji-Qiang Li; De-Kai Qiu; Jing-Yuan Fang; Ai-Ping Cao; Mo-Bin Wan; Cheng-Zhong Li; Jun Ye; Xiong Cai; Cheng-Wei Chen; Ji-Yao Wang; Shan-Ming Wu; Jin-Shui Zhu; Xia-Qiu Zhou
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

7.  Effects of heparin on liver fibrosis in patients with chronic hepatitis B.

Authors:  Jun Shi; Jing-Hua Hao; Wan-Hua Ren; Ju-Ren Zhu
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

8.  New serum biomarkers for detection of HBV-induced liver cirrhosis using SELDI protein chip technology.

Authors:  Xiao-Dong Zhu; Wei-Hua Zhang; Cheng-Lin Li; Yang Xu; Wei-Jiang Liang; Po Tien
Journal:  World J Gastroenterol       Date:  2004-08-15       Impact factor: 5.742

Review 9.  Alcoholic and non-alcoholic steatohepatitis.

Authors:  Manuela G Neuman; Samuel W French; Barbara A French; Helmut K Seitz; Lawrence B Cohen; Sebastian Mueller; Natalia A Osna; Kusum K Kharbanda; Devanshi Seth; Abraham Bautista; Kyle J Thompson; Iain H McKillop; Irina A Kirpich; Craig J McClain; Ramon Bataller; Radu M Nanau; Mihai Voiculescu; Mihai Opris; Hong Shen; Brittany Tillman; Jun Li; Hui Liu; Paul G Thomes; Murali Ganesan; Steve Malnick
Journal:  Exp Mol Pathol       Date:  2014-09-11       Impact factor: 3.362

10.  Grading and staging of hepatic fibrosis, and its relationship with noninvasive diagnostic parameters.

Authors:  Lun-Gen Lu; Min-De Zeng; Mo-Bin Wan; Cheng-Zhong Li; Yi-Min Mao; Ji-Qiang Li; De-Kai Qiu; Ai-Ping Cao; Jun Ye; Xiong Cai; Cheng-Wei Chen; Ji-Yao Wang; Shan-Ming Wu; Jin-Shui Zhu; Xia-Qiu Zhou
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.